» Articles » PMID: 20801068

Differences in the Predominance of Lysosomal and Autophagic Pathologies Between Infants and Adults with Pompe Disease: Implications for Therapy

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2010 Aug 31
PMID 20801068
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase, the enzyme that degrades glycogen in the lysosomes. The disease manifests as a fatal cardiomyopathy and skeletal muscle myopathy in infants; in milder late-onset forms skeletal muscle is the major tissue affected. We have previously demonstrated that autophagic inclusions in muscle are prominent in adult patients and the mouse model. In this study we have evaluated the contribution of the autophagic pathology in infants before and 6 months after enzyme replacement therapy. Single muscle fibers, isolated from muscle biopsies, were stained for autophagosomal and lysosomal markers and analyzed by confocal microscopy. In addition, unstained bundles of fixed muscles were analyzed by second harmonic imaging. Unexpectedly, the autophagic component which is so prominent in juvenile and adult patients was negligible in infants; instead, the overwhelming characteristic was the presence of hugely expanded lysosomes. After 6 months on therapy, however, the autophagic buildup becomes visible as if unmasked by the clearance of glycogen. In most fibers, the two pathologies did not seem to coexist. These data point to the possibility of differences in the pathogenesis of Pompe disease in infants and adults.

Citing Articles

An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion.

Colburn R, Lapidus D Front Pediatr. 2024; 11:1221140.

PMID: 38274468 PMC: 10810242. DOI: 10.3389/fped.2023.1221140.


Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management.

Bolano-Diaz C, Diaz-Manera J Ther Clin Risk Manag. 2022; 18:1099-1115.

PMID: 36536827 PMC: 9759116. DOI: 10.2147/TCRM.S334232.


The Clinical Management of Pompe Disease: A Pediatric Perspective.

Marques J Children (Basel). 2022; 9(9).

PMID: 36138713 PMC: 9497581. DOI: 10.3390/children9091404.


Neuromuscular Development and Disease: Learning From and Models.

Fralish Z, Lotz E, Chavez T, Khodabukus A, Bursac N Front Cell Dev Biol. 2021; 9:764732.

PMID: 34778273 PMC: 8579029. DOI: 10.3389/fcell.2021.764732.


Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?.

Krag T, Holm-Yildiz S, Witting N, Vissing J Acta Neuropathol Commun. 2021; 9(1):109.

PMID: 34120654 PMC: 8201813. DOI: 10.1186/s40478-021-01212-8.


References
1.
Kishnani P, Hwu W, Mandel H, Nicolino M, Yong F, Corzo D . A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006; 148(5):671-676. DOI: 10.1016/j.jpeds.2005.11.033. View

2.
Levine B, Kroemer G . Autophagy in the pathogenesis of disease. Cell. 2008; 132(1):27-42. PMC: 2696814. DOI: 10.1016/j.cell.2007.12.018. View

3.
Chien Y, Chiang S, Zhang X, Keutzer J, Lee N, Huang A . Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008; 122(1):e39-45. DOI: 10.1542/peds.2007-2222. View

4.
van den Hout H, Hop W, van Diggelen O, Smeitink J, Smit G, Poll-The B . The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003; 112(2):332-40. DOI: 10.1542/peds.112.2.332. View

5.
Fukuda T, Ahearn M, Roberts A, Mattaliano R, Zaal K, Ralston E . Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther. 2006; 14(6):831-9. PMC: 2693339. DOI: 10.1016/j.ymthe.2006.08.009. View